Partner portal 
1900 1034 17-OH-Progesterone test is used for screening and diagnosing Congenital Adrenal Hyperplasia (CAH).
The test measures a hormone called hCG, produced during pregnancy by the placenta and found in the blood and urine. Testing for hCG can be done as early as ten days after conception to determine if you are pregnant. Measuring hCG can also help identify potential complications.
First-trimester screening has three parts, an ultrasound test for fetal nuchal translucency (NT), PAPP-A, and hCG. When used together, NT screening and maternal blood tests can better determine potential birth defects, such as Down syndrome, Edward syndrome, or Patau syndrome. Amniocentesis or other ultrasound procedures may also be necessary for accurate diagnosis if the results are abnormal.
HPV is short for human papillomavirus, a very common sexually transmitted infection divided into different types, each identified with a number. HPV types including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 are high-risk types known to significantly increase the risk of cervical, vaginal, and vulvar cancer in women, as well as penile cancer in men. These types can also cause anal cancer and throat cancers in men and women.
HPV is short for human papillomavirus, a very common sexually transmitted infection divided into different types, each identified with a number. High-risk HPVs (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) can cause several types of cancer. Two of these, HPV16 and HPV18, are responsible for most HPV-related cancers. Low-risk HPVs are mostly asymptomatic. Sometimes, they may cause warts on or around the genitals, anus, mouth, or throat.
HPV is short for human papillomavirus, a very common sexually transmitted infection divided into different types, each identified with a number. High-risk HPVs (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) can cause several types of cancer. Two of these, HPV16 and HPV18, are responsible for most HPV-related cancers. Low-risk HPVs are mostly asymptomatic. Sometimes, they may cause warts on or around the genitals, anus, mouth, or throat.
The NIPT package represents a more advanced version of the standard non-invasive prenatal test, elevating the screening process by checking for common chromosomal abnormalities, variations in sex chromosomes, and specific genetic mutations. This includes screening for conditions such as Klinefelter syndrome (XXY), Triple X syndrome (XXX), a more severe variant of Klinefelter Syndrome (XXXY), and Jacobs Syndrome (XYY). Additionally, it screens for 2,800 mutant variables causing single-gene diseases inherited from the mother, alongside 495 deletions and mutations causing Alpha & Beta Thalassemia in the mother. The exceptional feature of the NIPT package is the inclusion of the NIPT Carrier test as a bonus. This test evaluates 9 potential genetic diseases where the person tested may be a carrier. It is particularly beneficial for expectant mothers seeking to understand their risk of passing certain genetic conditions onto their child. With this thorough analysis, the NIPT package provides crucial information about the fetus's health and genetic makeup to expectant parents and healthcare professionals. This information can aid in making informed decisions about pregnancy management and is an essential part of prenatal care for individuals with specific genetic concerns or those seeking peace of mind.
NIPT 3 is an upgrade choice of the Non-Invasive Prenatal Testing Panel and includes screening for Turner Syndrome (Monosomy X or XO). This condition is identified by the presence of a single X chromosome in females instead of the usual two (XX). NIPT 3 analyzes fetal DNA in the mother's blood to detect Turner Syndrome and other chromosomal abnormalities early in the pregnancy. By identifying potential conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13), and Turner Syndrome, NIPT 3 offers comprehensive insight into the fetus's chromosomal health. This early detection is crucial for planning medical management and counseling for expectant parents, providing valuable information about their baby's health and any potential genetic conditions.
The NIPT 9.5 is an expanded version of the standard non-invasive prenatal test. It offers comprehensive screening for a wider range of genetic conditions, including common chromosomal abnormalities, sex chromosome variations, and specific genetic mutations. The screened conditions include Klinefelter syndrome (XXY), Triple X syndrome (XXX), a more severe variant of Klinefelter Syndrome (XXXY), and Jacobs Syndrome (XYY). Furthermore, it looks for 2,800 mutant disease-causing variables related to single-gene diseases that are inherited from the mother, alongside 495 deletions and mutations causing Alpha & Beta Thalassemia in the mother. Additionally, this package includes the NIPT Carrier test as a promotional feature, which screens for 9 potential genetic diseases where the person tested may be a carrier. This is particularly valuable for expectant mothers who want to understand their risk of passing certain genetic conditions onto their child. By offering such a comprehensive analysis, the NIPT 9.5 package provides expectant parents and healthcare professionals with crucial information about the fetus's health and genetic makeup, aiding in informed decision-making regarding pregnancy management. This advanced screening can be an integral part of prenatal care for those with specific genetic concerns or who simply seek peace of mind.
NIPT First is a type of NIPT (Non-Invasive Prenatal Testing) which is a pregnancy screening test. It detects potential congenital defects caused by chromosomal abnormalities such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). The test examines small fragments of fetal DNA in the mother's blood to assess the risk of these chromosomal anomalies. This provides important information for expectant parents and healthcare providers about the fetus's health. It's a non-invasive option, which minimizes risks to both the mother and fetus, while offering early insights into potential genetic concerns.
The NIPT Procare is a groundbreaking advancement in prenatal screening tests that has set a new standard in Vietnam for the evaluation of dominant single-gene inherited disorders. This enhanced version of the NIPT is capable of accurately identifying 25 prevalent dominant single-gene diseases using just a single sample of maternal blood. This capability exceeds the collective incidence of Down syndrome. The NIPT Procare is designed specifically for expectant mothers who wish to assess the likelihood of transmitting specific genetic conditions to their offspring. Its early detection capabilities can provide valuable information as early as nine weeks into gestation, allowing for timely interventions and effective treatment strategies for newborns. This comprehensive upgrade in non-invasive prenatal testing emphasizes the importance of early screening and has the potential to significantly impact the field of prenatal care.
A Pap smear is where cells are collected from the cervix and sent to a lab to check for signs of cancer or for HPV, a virus that can cause cervical cancer. Pap smears and HPV tests are cervical cancer screening tests that look for cancer before you have any symptoms.
Personal use only test to confirm bloodline genetic DNA relationship between a child and a relative on the father's side.
